Ipamorelin
Ipamorelin is a defined peptide research entity with its own identity and evidence base. In a product containing both ipamorelin and CJC-1295, each component still needs an explicit specification. Sharing a container does not merge their molecular identities or research findings.
Read the molecular record
The original ipamorelin paper describes a pentapeptide and its experimental selectivity profile. A supplier record should preserve the sequence, nonstandard residues or stereochemistry, terminal groups and salt rather than relying on the short name alone. [1]
| Field | Why it belongs in the specification |
|---|---|
| Exact structure | Distinguishes the intended entity from a related peptide |
| Form | Defines salt and other relevant composition |
| Component amount | States what the declared quantity represents |
| Analytical identity | Connects the sample result to that entity |
| Blend configuration | Identifies the combined presentation actually supplied |
Selectivity has an experimental boundary
Raun and colleagues' work included comparative hormone responses in swine. Those measurements support a model-specific selectivity account; they do not establish absence of all other effects or safety for personal use. [1]
Gobburu and colleagues examined disposition and hormone-response modelling in healthy male volunteers. A single-compound pharmacokinetic estimate cannot establish the kinetics of a commercial co-formulation. [2]
Retain the clinical null finding
In the postoperative-ileus trial reported by Beck and colleagues, the key efficacy comparison was not statistically significant; the reported p value was 0.15. A numerical difference between groups should not be described as demonstrated efficacy. The trial preparation also does not verify the catalogue blend. [3]
Commercial context
The CJC-1295/ipamorelin product owns the offered presentation. Use the component comparison to identify the separate CJC variant question and single compounds versus blends for the evidence required when both are supplied together.
Request the exact component specifications and lot-matched records through batch documentation. The studies explain why the entity is researched; they do not measure the contents or performance of the supplied lot.
Before relying on a supplied report, use the Certificate of Analysis guide to connect its material, lot and test results.
Continue the material check
| Resource | Why open it |
|---|---|
| Receptor-Targeted Research Peptides | Browse receptor-related materials with variant limits visible. |
| Compound Index | Find another molecular profile without confusing it with a vial. |
| Receptor Agonists and Selectivity | Read binding, potency, efficacy and selectivity in context. |
| Co-Formulated Research Blends | Find the two blend records and their component-evidence questions. |
Sources and scope
- Raun et al. (1998). Ipamorelin selectivity experiments. European Journal of Endocrinology.Reference pentapeptide; ACTH/cortisol selectivity comparative and species/condition limited. Access: Original article abstract retrieved through official Europe PMC core record
- Gobburu et al. (1999). Ipamorelin disposition and hormone-response modelling. Pharmaceutical Research.Healthy male volunteers, IV study, ~2-hour terminal half-life; no blend kinetics inferred. Access: Original article abstract retrieved through official Europe PMC core record
- Beck et al. (2014). Ipamorelin postoperative-ileus trial. International Journal of Colorectal Disease.117 enrolled, 114 analysis population, 25.3/32.6 hours, p=0.15; key and secondary efficacy comparisons not significant. Access: Original article abstract retrieved through official Europe PMC core record